We believe that having invested and dedicated leadership begins with a management team that encourages innovation and creative thought processes amongst employees. Our management team encompasses a diverse background of experience and credentials that support and enhance our company’s goals.
The board of directors understands our company and takes the time to conduct thorough reviews and ask challenging questions in a continual effort to increase long-term shareholder value.
Brad provides overall leadership for CMP and leads strategic value creation and organizational transformation initiatives. Brad joined CMP in 2022 and has years of financial, accounting, and leadership experience in the industry with a focus on strategic planning, business development, financial modeling, operations, and team development. Brad held various finance leadership positions at SunTech Medical and Chiesi Pharmaceuticals prior to joining CMP. Brad has a BSBA in business/computer information systems from Appalachian State University, a Master of Accounting from the University of North Carolina at Chapel Hill, and is a licensed CPA in the state of North Carolina.
Anthony Pipho joined CMP Pharma in August 2014. Pipho brings over 25 years of experience in the pharmaceutical industry. Past experiences include various positions of increasing responsibility with Metrics, Inc. and CMP Pharma focusing on analytical, formulation, and process development of pharmaceutical products including solid, semi-solid, oral suspensions/solutions, and sterile injectable dosage forms. He is responsible for oversight of Operations at CMP Pharma including product development, commercial manufacturing, regulatory, purchasing and logistics. He has a Bachelor of Science degree in biochemistry from East Carolina University.
Jonathan Kuhn joined CMP Pharma in June 2017. Jon brings over 30 years of pharmaceutical industry experience including over 25 years of branded pharmaceutical marketing and several product launches. Previous positions include Senior Director, U.S. Parkinson’s Disease & Neuropathic Pain Marketing and Director U.S. & Global, Multiple Sclerosis & Spasticity Brand Marketing at Acorda Therapeutics. He has a Bachelor’s of Science in management from the University of Bloomsburg and has an MBA in marketing from DeSales University.
Melanie Little Joined CMP Pharma in February 2017. Little brings 20 years of related pharmaceutical quality experience to the team. Previous positions include QA Specialist, QA Supervisor, Principal Quality Associate, Regulatory Compliance Audit Support for DSM Pharmaceuticals, Metrics, Inc. and Mayne Pharma, Inc. Melanie has an Associates of Applied Science in Biotechnology from Pitt Community College.
Emily joined CMP in 2024. She has a strong background in both legal and compliance throughout the healthcare industry. She began her career with Chiesi Pharmaceuticals Inc. where she served as Managing Counsel and Privacy Officer. She then moved to a position in telehealth with Teladoc Inc. After taking on the role of Vice President and Corporate Counsel, she ventured into the device space as Sr. Corporate Counsel and Director of Global Privacy for Embecta, Inc. In all her roles, she focused on building compliance and privacy programs while providing legal guidance on a diverse range of topics for global teams. She has a BA from North Carolina State University in International Studies and a Juris Doctor from Campbell School of Law.
John Dilda joined CMP Pharma in 1986. Dilda brings 30 years of pharmaceutical manufacturing experience and earned an Associate degree in Applied Science.
Mr. Callahan currently serves as an independent advisor to global biopharmaceutical companies. Previously, he spent over two decades in leadership positions within the industry, most recently serving as SVP, Commercial Operations at Actavis (now Allergan). Prior to this, Mr. Callahan held positions of increasing responsibility in general management and commercial leadership at Actavis, Watson Pharmaceuticals, and Schein Pharmaceutical. Mr. Callahan serves on the Board of Directors for Synergy Pharmaceuticals (NASDAQ: SGYP), and he is a Senior Advisor to McKinsey & Company. Mr. Callahan holds a Bachelor of Science degree in Applied Economics and Business Management from Cornell University.
Matteo is a principal at Altaris. Prior to joining Altaris, Matteo was a member of the private equity and healthcare practices of McKinsey & Company where he completed numerous transaction and corporate strategy engagements. Matteo received a Doctor of Medicine degree from the University of Turin, Italy.
Previously, Steve served as CEO of Moberg Pharma North America (formerly Alterna LLC) and prior to that was a principal management team member of Sparta Systems, where he served in various sales, marketing, and operational roles. He is currently the CEO of Clearwater, a healthcare focused cybersecurity and risk management company focused on serving the healthcare industry. Mr. Cagle received a Bachelor of Science from Rutgers and a Master of Business Administration from NYU Stern School of Business.
Garikai is a principal at Altaris. Prior to joining Altaris, Garikai was an engagement manager in the private equity and healthcare practices of McKinsey & Company where he completed numerous transaction and corporate strategy engagements. Garikai received an M.S. in Financial Economics from Oxford University and a B.S. in Economics from The University of Cape Town.
